Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET
Company Participants
Jennifer Simpson – Chief Executive Officer
Sue Horvath – Chief Financial Officer
Conference Call Participants
Tony Butler – ROTH Capital
Operator
Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Panbela Therapeutics Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After management’s prepared remarks, there will be a question-and-answer session.
With me on the call are Jennifer Simpson, Chief Executive Officer; and Sue Horvath, Chief Financial Officer.
Before I turn the call over to Dr. Simpson, please note that statements made on this call that are not historical facts may be forward-looking statements. Significant risks and uncertainties that could cause actual results to differ from those expressed or implied in the forward-looking statements are detailed in the company’s Annual Report on Form 10-K and supplemented by subsequently filed quarterly reports on Form 10-Q as well in other reports that the company has filed with the SEC.
Any forward-looking statements made on this call are made only as of today’s date and the company does not undertake any obligation to update or supplement any such statements to reflect subsequent developments.
Now, I would like to turn the call over to Jennifer Simpson, CEO of Panbela. Jennifer, please proceed.
Jennifer Simpson
Thank you, and thank you, everyone, for joining. I will begin the call by touching on Q2 and our recent significant accomplishments. Sue will then follow with the review of the financial results, and then we will open it up for Q&A.
So starting with Q2 and recent highlights, since our last earnings call, we have closed on our acquisition of Cancer Prevention Pharmaceuticals or CPP for short, as we’ve shared, a combined company will have a much larger pipeline targeting approximately a $5 billion aggregate market opportunity for the areas of initial focus.
Acquiring CPP has substantially advanced our mission of treating diseases, where there are unmet medical needs, through a diversified pipeline, addressing numerous targets and thus expanding the potential of a combined company. CPP’s primary assets eflornithine or CPP-1X is being evaluated in clinical trials in combination, and in two additional forms, a tablet and a sachet.
In a Phase 3 study, the efficacy and safety of a combination of eflornithine and sulindac for Flynpovi as compared with either eflornithine or sulindac alone in adults with familial adenomatous polyposis also known as FAP was completed in 2019, a total of 171 patients under one – underwent randomization. The primary endpoint was an event driven composite endpoint, which the study failed to show a statistical difference.